Year-end Sale % OFF 
Abstract
Traditionally, β-blockers, used as first-line agents to treat uncomplicated hypertension, were recommended by national and international guidelines despite a paucity of evidence regarding their cardiovascular benefit. However, evidence from recent trials and metaanalyses has questioned the use of β-blockers as preferred agents. This article reviews the data available from clinical trials and argues that β-blockers are less efficacious than other currently available antihypertensive agents for patients with uncomplicated hypertension.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
